Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged ≥40 yrs~* Smoking history of at least 10 pack years~* Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)~* Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) \<70%~Exclusion Criteria:~* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular co-morbid conditions~* Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency~* Patients in the active phase of a supervised pulmonary rehabilitation program~* Patients contraindicated for inhaled anticholinergic agents and β2 agonists~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- indacaterol and glycopyrronium (QVA149) (Type: EXPERIMENTAL): QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
- glycopyrronium (NVA237) (Type: ACTIVE_COMPARATOR): NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
- indacaterol (QAB149) (Type: ACTIVE_COMPARATOR): QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
- tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete